Evotec

The collaboration will involve Evotec's Panomics platform, which integrates the analysis of genomic, transcriptomic, and proteomic data.


The companies will combine their respective technologies to create a platform for discovering and developing drugs for certain genetic diseases.

The deal expands Evotec's existing CRISPR licenses through the Broad Institute and adds to ERS's list of licensees for its gene editing technology.

Evotec will gain non-exclusive rights to Ncardia IP, including a broad panel of stem cell-derived cell lines for use in drug target discovery and testing.

Evotec will use Merck's collection of genetic reagents — including viral CRISPR and shRNA libraries — in target discovery programs.

Evotec may use the technology for its drug-development and R&D activities, including in the development of research tools and in target identification.

NEW YORK (GenomeWeb News) – Evotec said today that the CHDI Foundation has extended and expanded the two parties' collaboration on Huntington's disease research through 2017.

NEW YORK (GenomeWeb) – Evotec said this week that it has achieved a milestone in its protein biomarker work with Roche, as the drugmaker selected for phase I clinical trial use a response prediction marker developed through the two firms' collaboration.

NEW YORK (GenomeWeb News) – Evotec today said that it has forged an alliance with the Harvard Stem Cell Institute to identify compounds that can prevent or slow down the loss of motor neurons, a characteristic of amyotrophic lateral sclerosis.

Pages

The Washington Post reports on a Federal Bureau of Investigation plan to place rapid DNA analyzers at booking stations around the country.

In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.

The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.

In Science this week: the PsychENCODE Consortium reports on the molecular mechanisms of neuropsychiatric disorders, and more.